Abstracts tagged "Randomized Trial"

Abstract Number: 1485 • ACR Convergence 2020
LNA043, a Novel Cartilage Regenerative Treatment for Osteoarthritis: Results from a First-In-Human Trial in Patients with Knee Osteoarthritis
Celeste Scotti¹, Joseph Gimbel², Didier Laurent¹, Aviv Madar³, Thomas Peters¹, Yunyu Zhang³, Florine Polus¹, Michael Beste³, Igor Vostiar¹, Subhajit Choudhury⁴, Nicole Gerwin¹, Jörg Goldhahn⁵, Matthias Schieker¹ and Ronenn Roubenoff¹, ¹Novartis Institutes for BioMedical Research, Basel, Switzerland, ²Arizona Research Center, Phoenix, ³Novartis Institutes for BioMedical Research, Cambridge, ⁴Biostatistics & Pharmacometrics, Novartis Healthcare Pvt. Ltd., Hyderabad, India, ⁵Department of Health Sciences and Technology, ETH Zürich, Zurich, Switzerland
Background/Purpose:LNA043 is a modified human angiopoietin-like 3 (ANGPTL3) protein identified in a phenotypic screen for inducers of chondrogenesis and cartilage repair. The primary objective of…
Abstract Number: 0200 • ACR Convergence 2020
Predictors of Durable Clinical Response to Tofacitinib 11 Mg Once Daily with or Without Methotrexate in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Data from a Phase 3b/4 Methotrexate Withdrawal Study
Kunihiro Yamaoka¹, Stanley B Cohen², Naonobu Sugiyama³, Harry Shi⁴, Jose L Rivas⁵, Annette Diehl⁴ and Josef Smolen⁶, ¹Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan, ²Metroplex Clinical Research Center, Dallas, TX, ³Pfizer Japan Inc, Tokyo, Japan, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer SLU, Madrid, Spain, ⁶Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: ORAL Shift, a global Phase 3b/4 non-inferiority study, demonstrated sustained efficacy/safety of tofacitinib modified-release (MR) 11 mg QD following MTX withdrawal in patients (pts)…
Abstract Number: 0962 • ACR Convergence 2020
Efficacy of Clomipramine for Chronic Lumbar Radicular Pain a Randomized Clinical Trial
Saloua Afilal¹, Safaa Fellous¹, Ilham Aachari¹, Redouane Abouqal², Ihsane Hmamouchi³, Nada Alami¹, Latifa Tahiri¹, Hanan Rkain¹, Najia Hajjaj-Hassouni⁴ and Fadoua Allali¹, ¹Rheumatology B Department, El Ayachi Hospital, Faculty of Medicine and Pharmacy of Rabat, Mohammed V University, Rabat, Morocco., Rabat, Morocco, ²Laboratory of Biostatistics, Clinical Research and Epidemiology (LBRCE), Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco., Rabat, Morocco, ³Temara Hospital, Laboratory of Biostatistics, Clinical Research and Epidemiology (LBRCE), Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco, Rabat, Morocco, ⁴Health Sciences College, International University of Rabat (UIR), Rabat, Morocco
Background/Purpose: Lumbar radicular pain is the most common chronic neuropathic pain syndrome. Antidepressants are highly recommended for neuropathic pain, but there is no evidence for…
Abstract Number: 1486 • ACR Convergence 2020
Long-term Efficacy and Safety of Intra-articular Sprifermin in Patients with Knee Osteoarthritis: Results from the 5-Year Forward Study
Felix Eckstein¹, Marc Hochberg², Hans Guehring³, Flavie Moreau⁴, Victor Ona⁴, Asger Bihlet⁵, Inger Byrjalsen⁵, Jeppe Andersen⁵, Benjamin Daelken³, Oliver Guenther³, Christoph Ladel³, Martin Michaelis³ and Philip G Conaghan⁶, ¹Paracelsus Medical University, Salzburg, Austria, ²University of Maryland School of Medicine, Baltimore, MD, ³Merck KGaA, Darmstadt, Germany, ⁴EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁵Nordic Bioscience, Herlev, Denmark, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health Research Leeds Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: The 5-year Phase II FORWARD study assessed the efficacy and safety of the potential disease-modifying osteoarthritis drug (DMOAD) sprifermin (recombinant human fibroblast growth factor…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].